logo
ENTITY
CStone Pharmaceuticals

CStone Pharmaceuticals (2616 HK)

91
Analysis
Health Care • Hong Kong
CStone Pharmaceuticals operates as a biotechnology company. The Company develops immuno-oncology and molecularly targeted drugs to address unmet medical needs for cancer patients. CStone Pharmaceuticals serves customers worldwide.
more
Exchange Announcement • 23 Dec 2024 08:00

Voluntary Announcement - Cstone Announces Submission Of Clinical Trial Application In Australia For Cs2009, An Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody

Exchange Announcement • 19 Dec 2024 08:02

Voluntary Announcement - Cstone Announces First Patient Enrolled In The Global Multicenter Phase Ib Clinical Trial Of Cs5001 (Ror1 Adc)

Exchange Announcement • 09 Dec 2024 08:00

Voluntary Announcement - Cstone Presents Latest Clinical Data On Cs5001 For Advanced Lymphoma At The 66th Ash Annual Meeting

Exchange Announcement • 21 Nov 2024 08:00

Voluntary Announcement - Cstone And Pharmalink Enter Into Strategic Partnership For Sugemalimab In Middle East And North Africa Region And South Africa

Exchange Announcement • 11 Nov 2024 12:00

Voluntary Announcement - Cstone Presents Preclinical Data On Cs2009 At The 2024 Sitc Annual Meeting

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x